But what exactly is a "Crispr baby" anyway? Would you like to be 6 feet tall? Or never bald? The secret to traits like these lies in the 6 billion letters of your genetic code. But there can be ...

Researchers have developed a novel delivery system for sending CRISPR reagents to brain cells, where it performs its gene ...

Crispr Therapeutics recently received FDA and EMA approval for Casgevy. Read why CRSP stock is compelling investment in the ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

Almost half a century on from the first ‘test tube’ birth, IVF has been used by millions – yet some fear it heralds a ...

the latest shift for a tarantella company that has repeatedly switched direction and leadership since first emerging as one of the first CRISPR biotechs a decade ago. Editas will now focus ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

CRISPR Therapeutics recently proved it was capable of getting a drug approved. Next, its oncology and cardiovascular disease programs will need to show value. It may soon face some financial ...

Canadian officials show that reviewing emerging supply chain issues and taking steps to limit potential problems worked in its favor. Also in the news: noncompete bans, schizophrenia drugs, baby ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...